⌘K

Login Start Free

Home/Filings/4/0001209191-20-047504

4//SEC Filing

Olson Eric R 4

Accession 0001209191-20-047504

CIK 0001556263other

View on SEC.gov Company Profile

Filed

Aug 18, 8:00 PM ET

Accepted

Aug 19, 4:35 PM ET

Size

13.9 KB

Accession

0001209191-20-047504

Insider Transaction Report

Form 4

Period: 2020-08-17

Syros Pharmaceuticals, Inc.SYRS

Chief Scientific Officer

Transactions

Sale
Common Stock
2020-08-18$13.00/sh−10,787$140,231→ 0 total
Exercise/Conversion
Common Stock
2020-08-17$1.01/sh+4,963$5,013→ 4,963 total
Exercise/Conversion
Stock Option (right to buy)
2020-08-17−4,963→ 105,112 total
Exercise: $1.01Exp: 2023-05-22→ Common Stock (4,963 underlying)
Exercise/Conversion
Common Stock
2020-08-18$1.01/sh+10,787$10,895→ 10,787 total
Sale
Common Stock
2020-08-17$13.00/sh−4,963$64,519→ 0 total
Exercise/Conversion
Stock Option (right to buy)
2020-08-18−10,787→ 94,325 total
Exercise: $1.01Exp: 2023-05-22→ Common Stock (10,787 underlying)

Footnotes (2)

[F1]The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
[F2]This option is fully vested.

Documents

1 file

4
doc4.xmlPrimary
FORM 4 SUBMISSION

Issuer

Syros Pharmaceuticals, Inc.

CIK 0001556263

Entity typeother

Related Parties

1

filerCIK 0001678149

Filing Metadata

Form type: 4
Filed: Aug 18, 8:00 PM ET
Accepted: Aug 19, 4:35 PM ET
Size: 13.9 KB

View on SEC.gov